Video

ODYSSEY Alternative Trials Show Promise for Hypercholesterolemia Patients

Author(s):

For patients with a statin intolerance, getting the treatment they need to manage their cholesterol levels can be difficult. A recent study has shown that a new class of drugs known as PCSK9 inhibitors could help effectively manage cholesterol levels in this patient population.

For patients with a statin intolerance, getting the treatment they need to manage their cholesterol levels can be difficult. A recent study has shown that a new class of drugs known as PCSK9 inhibitors could help effectively manage cholesterol levels in this patient population..

Patrick Moriarty, MD, FACC, FACP, from the University of Kansas Medical Center, presented findings from the Phase 3 alirocumab ODYSSEY trial during the 2014 American Heart Association Scientific Sessions in Chicago, IL.

Related Videos
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.